JP2016138129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016138129A5 JP2016138129A5 JP2016078639A JP2016078639A JP2016138129A5 JP 2016138129 A5 JP2016138129 A5 JP 2016138129A5 JP 2016078639 A JP2016078639 A JP 2016078639A JP 2016078639 A JP2016078639 A JP 2016078639A JP 2016138129 A5 JP2016138129 A5 JP 2016138129A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fcγriib
- composition
- target cell
- antibody molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1013989.7 | 2010-08-20 | ||
| GBGB1013989.7A GB201013989D0 (en) | 2010-08-20 | 2010-08-20 | Biological materials and methods of using the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Division JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016138129A JP2016138129A (ja) | 2016-08-04 |
| JP2016138129A5 true JP2016138129A5 (enExample) | 2017-06-08 |
| JP6421140B2 JP6421140B2 (ja) | 2018-11-07 |
Family
ID=42984443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Active JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
| JP2016078639A Active JP6421140B2 (ja) | 2010-08-20 | 2016-04-11 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Active JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10525129B2 (enExample) |
| EP (2) | EP3263602A1 (enExample) |
| JP (2) | JP6215704B2 (enExample) |
| KR (1) | KR101948609B1 (enExample) |
| CN (8) | CN114099668B (enExample) |
| AU (1) | AU2011290503B2 (enExample) |
| CA (1) | CA2808744C (enExample) |
| DK (1) | DK2606068T3 (enExample) |
| ES (1) | ES2653685T3 (enExample) |
| GB (1) | GB201013989D0 (enExample) |
| HU (1) | HUE037478T2 (enExample) |
| NO (1) | NO2606068T3 (enExample) |
| PL (1) | PL2606068T3 (enExample) |
| PT (1) | PT2606068T (enExample) |
| RU (2) | RU2769949C2 (enExample) |
| SI (1) | SI2606068T1 (enExample) |
| WO (1) | WO2012022985A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201013989D0 (en) * | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| EP2925351A4 (en) * | 2012-11-29 | 2016-08-24 | Bayer Healthcare Llc | MONOCLONAL ANTIBODIES DIRECTED AGAINST ACTIVATED PROTEIN C (APC) |
| EP3524691A1 (en) * | 2012-12-07 | 2019-08-14 | SuppreMol GmbH | Stratification and treatment of patients of idiopathic thrombocytopenic purpura |
| EP2970487B1 (en) | 2013-03-12 | 2020-03-11 | Molecular Templates, Inc. | Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types |
| EP2833139A1 (en) * | 2013-08-01 | 2015-02-04 | SuppreMol GmbH | In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s) |
| KR20160113158A (ko) | 2014-01-27 | 2016-09-28 | 몰레큘러 템플레이츠, 인코퍼레이션. | 폴리펩티드를 전달하는 mhc 클래스 i 항원결정기 |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
| US10815469B2 (en) | 2014-06-11 | 2020-10-27 | Molecular Templates, Inc. | Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties |
| JP6444486B2 (ja) | 2015-02-05 | 2018-12-26 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | 志賀毒素ａサブユニットエフェクター領域を含む多価ｃｄ２０結合分子及びそれらの強化組成物 |
| WO2016146702A1 (en) * | 2015-03-16 | 2016-09-22 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Trispecific binding molecules for treating hbv infection and associated conditions |
| JP6771492B2 (ja) | 2015-05-30 | 2020-10-21 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | 脱免疫化された志賀毒素ａサブユニット足場及びそれを含む細胞標的化分子 |
| UY37030A (es) | 2015-12-18 | 2017-07-31 | Novartis Ag | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos |
| CA3046489A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| JP7075134B2 (ja) | 2016-12-07 | 2022-05-25 | モレキュラー テンプレーツ，インク． | 部位特異的コンジュゲーションのための志賀毒素ａサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子 |
| KR102590672B1 (ko) | 2017-01-25 | 2023-10-18 | 몰레큘러 템플레이츠, 인코퍼레이션. | 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자 |
| JP2020505418A (ja) | 2017-01-30 | 2020-02-20 | オハイオ・ステイト・イノベーション・ファウンデーション | 受動抗体依存性細胞媒介活性化 |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2018229706A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Combination therapy for the treatment of cancer |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| CA3083949A1 (en) | 2017-11-30 | 2020-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| MX2019009726A (es) | 2018-04-17 | 2020-02-05 | Molecular Templates Inc | Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados. |
| CN108823211A (zh) * | 2018-05-04 | 2018-11-16 | 中国医学科学院基础医学研究所 | 一种cd19核酸适配体及其应用 |
| KR20250151605A (ko) | 2018-06-01 | 2025-10-21 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| AU2020315163B2 (en) * | 2019-07-17 | 2025-11-20 | Bioinvent International Ab | Antibody combinations for treatment of cancer in specific patients |
| WO2021076196A1 (en) * | 2019-10-18 | 2021-04-22 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| EP3919077A1 (en) | 2020-06-04 | 2021-12-08 | BioInvent International AB | Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies |
| US20230322933A1 (en) | 2020-06-04 | 2023-10-12 | Bioinvent International Ab | Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies |
| IL302569A (en) | 2020-11-06 | 2023-07-01 | Novartis Ag | Cd19 binding molecules and uses thereof |
| TW202336033A (zh) | 2022-03-07 | 2023-09-16 | 瑞典商生物創新國際有限公司 | 抗體之新穎組合及用途 |
| TW202346359A (zh) | 2022-04-15 | 2023-12-01 | 美商凱維那醫療公司 | 用於治療自體免疫疾病之方法及組合物 |
| WO2023240064A1 (en) | 2022-06-08 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| CA2109528A1 (en) | 1991-05-01 | 1992-11-02 | Gregory A. Prince | A method for treating infectious respiratory diseases |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| DK0885002T3 (da) | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materialer og fremgangsmåder til forøgelse af cellulær internalisering |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| CA2277801C (en) | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2001034194A1 (en) * | 1999-11-08 | 2001-05-17 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| US7425620B2 (en) | 2002-08-14 | 2008-09-16 | Scott Koenig | FcγRIIB-specific antibodies and methods of use thereof |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| AU2003265522A1 (en) | 2003-08-18 | 2005-03-10 | Macrogenics, Inc. | FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| AU2004293184B2 (en) | 2003-11-26 | 2010-12-16 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Substance binding human IgG Fc receptor IIb |
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| MXPA06011796A (es) | 2004-04-16 | 2007-05-07 | Macrogenics Inc | Anticuerpos especificos de fc(riib y metodos para el uso de los mismos. |
| MXPA06012601A (es) * | 2004-05-10 | 2007-05-10 | Macrogenics Inc | Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos. |
| CA2566535A1 (en) * | 2004-05-20 | 2006-05-11 | St. Mary's Hospital Nhs Trust | Ige-retargeting, function-altering molecules (erfam) for treatment of allergic diseases |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| WO2006066078A2 (en) | 2004-12-15 | 2006-06-22 | Magrogenics, Inc. | Fcϝriib-specific antibodies and methods of use thereof |
| EP1674479A1 (en) * | 2004-12-22 | 2006-06-28 | Memorial Sloan-Kettering Cancer Center | Modulation of Fc Gamma receptors for optimizing immunotherapy |
| EP2032159B1 (en) * | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| WO2009062083A2 (en) | 2007-11-08 | 2009-05-14 | Pikamab, Inc. | Methods and compositions for antibody therapy |
| US8802089B2 (en) * | 2008-01-03 | 2014-08-12 | Genmab A/S | Monoclonal antibodies against CD32B |
| CA2749215A1 (en) | 2009-01-08 | 2010-07-15 | The Uab Research Foudation | Process for regulating immune response |
| GB201013989D0 (en) | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
-
2010
- 2010-08-20 GB GBGB1013989.7A patent/GB201013989D0/en not_active Ceased
-
2011
- 2011-08-19 PL PL11760819T patent/PL2606068T3/pl unknown
- 2011-08-19 RU RU2017143633A patent/RU2769949C2/ru active
- 2011-08-19 HU HUE11760819A patent/HUE037478T2/hu unknown
- 2011-08-19 CN CN202110959354.9A patent/CN114099668B/zh active Active
- 2011-08-19 US US13/817,744 patent/US10525129B2/en active Active
- 2011-08-19 DK DK11760819.0T patent/DK2606068T3/da active
- 2011-08-19 CN CN202110959352.XA patent/CN114099666B/zh active Active
- 2011-08-19 SI SI201131366T patent/SI2606068T1/en unknown
- 2011-08-19 CN CN202110959481.9A patent/CN114099669A/zh active Pending
- 2011-08-19 ES ES11760819.0T patent/ES2653685T3/es active Active
- 2011-08-19 WO PCT/GB2011/051572 patent/WO2012022985A1/en not_active Ceased
- 2011-08-19 CN CN201710789909.3A patent/CN107670034B/zh active Active
- 2011-08-19 PT PT117608190T patent/PT2606068T/pt unknown
- 2011-08-19 CN CN202511469650.5A patent/CN121313820A/zh active Pending
- 2011-08-19 CN CN202110959353.4A patent/CN114099667B/zh active Active
- 2011-08-19 CA CA2808744A patent/CA2808744C/en active Active
- 2011-08-19 AU AU2011290503A patent/AU2011290503B2/en active Active
- 2011-08-19 CN CN201180040351XA patent/CN103080131A/zh active Pending
- 2011-08-19 EP EP17184259.4A patent/EP3263602A1/en not_active Withdrawn
- 2011-08-19 EP EP11760819.0A patent/EP2606068B1/en active Active
- 2011-08-19 KR KR1020137006990A patent/KR101948609B1/ko active Active
- 2011-08-19 JP JP2013524483A patent/JP6215704B2/ja active Active
- 2011-08-19 RU RU2013112345/10A patent/RU2013112345A/ru unknown
- 2011-08-19 NO NO11760819A patent/NO2606068T3/no unknown
- 2011-08-19 CN CN202110959355.3A patent/CN114099702B/zh active Active
-
2016
- 2016-04-11 JP JP2016078639A patent/JP6421140B2/ja active Active
-
2019
- 2019-11-14 US US16/684,450 patent/US11623005B2/en active Active
-
2021
- 2021-06-25 US US17/359,496 patent/US20210346498A1/en not_active Abandoned
-
2023
- 2023-03-01 US US18/177,050 patent/US12527866B2/en active Active